The Role of Radiotherapy in the Treatment of Portal Vein Thrombosis from Advanced Hepatocellular Carcinoma.
- Author:
Jung Hoon KIM
1
;
Eun Kyung CHOI
;
Seung Do AHN
;
Sang Wook LEE
;
Seong Soo SHIN
;
Wonsik CHOI
;
Young Suk LIM
;
Kang Mo KIM
;
Dong Jin SUH
;
Young Wha CHUNG
;
Young Sang LEE
;
Hyung Jin WON
;
Jong Hoon KIM
Author Information
1. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jhkim2@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Portal vein thrombosis;
Hepatocellular carcinoma;
Three-dimensional conformal radiotherapy
- MeSH:
Carcinoma, Hepatocellular*;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Liver;
Liver Diseases;
Portal Vein*;
Radiotherapy*;
Radiotherapy, Conformal;
Retrospective Studies;
Venous Thrombosis*
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2007;25(3):170-176
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To determine the role of radiotherapy for the treatment of portal vein thrombosis (PVT) from hepatocellular carcinoma (HCC). MATERIAL AND METHODS: A retrospective analysis was performed on 70 patients that had been diagnosed with HCC and were treated with three-dimensional conformal radiotherapy (3D-CRT) for the PVT. The radiation dose ranged from 40 Gy to 60 Gy (median dose: 48 Gy) and the biological effective dose (BED) ranged from 31.3 Gy to 78.0 Gy10 (median dose: 61.6 Gy10). Response was determined by measuring the extent of the PVT on a CT image at 0, 1 and 3 months after completion of the radiotherapy. The median follow-up period was 9 months. RESULTS: The response rate was 47.1% (33 patients), with two patients (2.9%) showing a complete response, 31 patients (44.3%) showing a partial response, and 35 patients (50%) showing stable disease or no response. The 1-year progression-free survival rate was 60%, and the median progression-free survival time was 17 months. The median overall survival time was 11 months, the median survival time in the responders was 15 months and in the nonresponders was 8 months (p=0.032). Four patients (5.7%) had transient liver function impairment during treatment. Radiation induced liver disease (RILD) was observed in only one patient (1.4%). CONCLUSION: Three-dimensional conformal radiotherapy for the treatment of PVT from advanced HCC was a relatively effective and safe method.
